Blog

Emma M. Groarke: We found that there was more than 40% cumulative incidence of venous and arterial thrombosis in patients with VEXAS

Photo from Emma M. Groarke/X

Feb 8, 2024, 14:58

Emma M. Groarke: We found that there was more than 40% cumulative incidence of venous and arterial thrombosis in patients with VEXAS

Emma M. Groarke, Hematologist at the National Institutes of Health (NIH), shared a post on X/Twitter:

“Very excited to share our NIH-Mayo Clinic collaboration just published in Blood Journal focused on the thrombotic manifestations occurring in VEXAS.

We found that there was >40% cumulative incidence of venous and arterial thrombosis in patients with VEXAS; many events occurred at initial disease presentation. Cardiac or pulmonary involvement appear to confer increased risk.

Thrombosis seems to be driven by inflammation. Patients almost ubiquitously had high FVIII levels and many had high VWD antigen and activity.”

Source: Emma M. Groarke/X

Blood Journal cancer Emma M. Groarke Mayo Clinic National Institutes of Health (NIH). NIH OncoDaily Oncology venous and arterial thrombosis Vexas VWD antigen

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

Special Coverage